Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04898361
Other study ID # PREDICT-AF PFO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 15, 2020
Est. completion date June 2022

Study information

Verified date May 2021
Source Universität des Saarlandes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interventional closure of patent foramen ovale (PFO) associates with reduced risk of stroke recurrence in patients with cryptogenic ischemic stroke as reported in the recent CLOSE and REDUCE trials. The long-term follow-up results of the RESPECT and DEFENSE-PFO trial confirmed these findings. PFO closure is therefore recommended in patient with cryptogenic ischemic stroke and PFO according to the current German interdisciplinary guidelines. It is likely that the number of PFO closure procedures will increase significantly in the near future. However, new onset atrial fibrillation (AF) appears to increase in patients following this procedure. In the REDUCE study, new onset atrial fibrillation was detected in 6.6% patients in the PFO closure group compared with 0.4% in the control group (medical treatment); 59% of these patients were diagnosed within the first two weeks following the procedure and 83% within 45 days, respectively. These results were consistent with the CLOSE study: AF was detected in 4.6% patients in the intervention group vs. 0.9% in the control group. Up until today, markers to identify and quantify the individual risk of AF onset are lacking. Furthermore, under-reporting and under-detection of AF occurrence after PFO closure is likely. This study is designed to to assess the prevalence and and identification of electrophysiological and echocardiographic parameters of new-onset AF.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2022
Est. primary completion date June 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Previous embolic stroke with undetermined source with… - palpitations with clinical indication for an electrophysiological study (control group) - PFO and clinical indication for interventional PFO closure according to current guidelines (intervention group) - Sinus rhythm at time of inclusion with no history of AF - Planned EP study due to reported palpitations or documented burden of non-sustained atrial arrythymias (>100 atrial ectopic beats /24 hours, atrial tachycardia) - Written informed consent Exclusion Criteria: - previously documented AF - indication for therapeutic anticoagulation - uncontrolled diabetes mellitus - acute coronary syndrom or acute cardiac decompensation within the last 6 months before enrollment - enrolled in another study - BMI > 40 kg/m² - patients who are pregnant of breastfeeding life expectancy < 6 months - relevant peripheral artery disease - substance abuse

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PFO closure
Interventional closure of a patent foramen oval preceded by an electrophysiological study

Locations

Country Name City State
Germany Universitätsklinikum des Saarlandes Homburg Saarland

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Saarland

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in baseline heart rhythm, e.g. new-onset atrial fibrillation Rate of detection of new-onset atrial fibrillation with Holter and loop recorder monitoring after electrophysiological study 1, 3, 6, 12 months
Secondary Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation 1 month
Secondary Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation 3 months
Secondary Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation 6 months
Secondary Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation 12 months
Secondary Change in left atrial morphology (LA volume index) following PFO closure Assessment of the change in left atrial morphology and function (LA volume index) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA volume index, physiologocal parameter 1 month
Secondary Change in left atrial function (LA strain) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 1 month
Secondary Change in new-onset AF following PFO closure Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG 1 month
Secondary Change in left atrial morphology (LA volume index) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 3 months
Secondary Change in left atrial function (LA strain) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 3 months
Secondary Change in new-onset AF following PFO closure Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG 3 months
Secondary Change in left atrial morphology (LA volume index) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 6 months
Secondary Change in left atrial function (LA strain) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 6 months
Secondary Change in new-onset AF following PFO closure Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG 6 months
Secondary Change in left atrial morphology (LA volume index) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 12 months
Secondary Change in left atrial function (LA strain) following PFO closure Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter 12 months
Secondary Change in new-onset AF following PFO closure Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG 12 months
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT04610463 - Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism N/A
Completed NCT02882815 - Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder N/A
Completed NCT04604015 - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt N/A
Active, not recruiting NCT04950192 - Philips Intracardiac Echocardiography (ICE) Clinical Registry
Not yet recruiting NCT04549272 - Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale
Completed NCT02621528 - Lifetech CeraFlex™ Post-Market Surveillance Study N/A
Terminated NCT01018355 - The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI N/A
Completed NCT00831259 - Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO) N/A
Not yet recruiting NCT05360771 - Study on the Safety and Effectiveness of the SnowyTM PFO Closure System N/A
Recruiting NCT05546320 - Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale Phase 4
Recruiting NCT05561660 - COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2) Phase 4
Completed NCT03904277 - Does Patent Foramen Ovale Size Matter in Men and Women
Recruiting NCT06120270 - CeraFlex PFO Closure System PMCF Study
Terminated NCT01773252 - Right to Left Cardiac Shunt Detection Phase 3
Completed NCT01216423 - Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale N/A
Completed NCT03377465 - Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis N/A
Active, not recruiting NCT04738071 - International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry
Not yet recruiting NCT06413147 - Long-term Procedural and Device Related Complications of PFO Closure
Not yet recruiting NCT06344494 - Cardiac Interventional ICE Imaging Trial N/A